🔓
Sign in as a Member to unlock the full view of ARQT. · Full hedge fund list, every line-item carveout, cabinet conflicts, and politicians-trading detail.
Become a Member$29.99/mo already a Member? Sign in →
ARQT

Arcutis Biotherapeutics, Inc.

Sector: pharmaBiotechnologyNASDAQMarket Cap: $3.17B

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on dermatological conditions, with its primary political signal being $5.03M in payments to doctors in 2024 and a single congressional trader executing offsetting trades.

Next filing → your inbox
Govt Dependence
85/100
Regulatory Density
95/100
Lobbying Intensity
0/100
Political Signal
NEUTRAL

BusinessWhat ARQT does

Arcutis Biotherapeutics develops and commercializes treatments for immune-mediated dermatological diseases. Its revenue is derived from product sales of its approved topical therapies and pipeline development. The company operates in the highly regulated pharmaceutical sector, subject to FDA oversight and drug pricing legislation.

12 months past · 3 months futureARQT activity timeline

$35$27$19 DecJan '26FebMarAprMayJunJulAugSepOctNovDecJan '27Feb ↓ PAST — recorded activity ↑ FUTURE — scheduled markups · pending votes TODAY · Nov 17 $34.05 hi $19.50 lo $27.15 CONGRESS 9 INSIDERS 0 13F FUNDS 30 BILLS 28 Gilbert Ray Cisneros (D) · Purchase · 2026-05-29Gilbert Ray Cisneros (D) · Purchase · 2026-03-03Gilbert Ray Cisneros (D) · Sale · 2025-12-11 D.E. Shaw & Co. · + $104M · 2026-06-30D.E. Shaw & Co. · + $59M · 2026-03-31D.E. Shaw & Co. · + $59M · 2025-12-31Citadel Advisors · + $33M · 2026-06-30Two Sigma Investments · + $17M · 2026-06-30Point72 Asset Management · OPENED $14M · 2026-03-31Renaissance Technologies · + $13M · 2026-09-30Two Sigma Investments · + $12M · 2025-12-31AQR Capital Management · OPENED $11M · 2026-03-31Renaissance Technologies · + $10M · 2026-03-31Point72 Asset Management · - $10M · 2026-06-30AQR Capital Management · - $9M · 2026-06-30Renaissance Technologies · OPENED $8M · 2025-12-31Two Sigma Investments · - $6M · 2026-03-31Citadel Advisors · - $5M · 2025-12-31Citadel Advisors · - $2M · 2026-03-31 MARKUP · Senate Veterans' Affairs · 2026-11-18MARKUP · Senate Health, Education, Labor, and Pensions · 2026-11-18MARKUP · Senate Veterans' Affairs · 2026-11-18
Congress
buy sell
Insider · Form 4
open-market buy
Hedge fund · 13F
opened + added − trimmed closed holds
Bills
past action (this ticker) upcoming markup (sector) ★ carveout (this ticker)
250 trading days · 3 congressional trades shown · 0 insider buys · 16 13F filings · 0 past bill actions · 3 upcoming markups

Lifetime Government AwardsARQT federal contracts

ARQT doesn't hold direct federal contracts.

Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.

Smart Money · 13F HoldingsHedge funds holding ARQT

$185.0M
Total ARQT held by tracked 13F funds
6
Funds with ARQT positions
D.E. Shaw & Co. $104M +58% 1 overlap 2026-06-30
Citadel Advisors $33M +1192% 1 overlap 2026-06-30
Two Sigma Investments $17M +183% 1 overlap 2026-06-30
Renaissance Technologies $13M +715% 2026-09-30
Point72 Asset Management $10M -39% 1 overlap 2026-06-30
AQR Capital Management $9M -29% 1 overlap 2026-06-30

Politicians Trading ARQTMembers of Congress with recent ARQT positions

1 politicians traded ARQT across 3 disclosed transactions totaling $24K (last 730 days). Greed score = composite of trade frequency, volume & recency across the politician's entire history (not just ARQT). 0-30 LOW · 30-60 MID · 60+ HIGH.

Congressional TradesWho in Congress is trading ARQT

2026-05-29 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000
2026-03-03 Gilbert Ray Cisneros D-California · house Purchase $1,001 - $15,000
2025-12-11 Gilbert Ray Cisneros D-California · house Sale $1,001 - $15,000
2023-09-15 Josh Gottheimer D-New Jersey · house sale $1,001 - $15,000
2023-09-15 Josh Gottheimer D-New Jersey · house Sale $1,001 - $15,000
2023-04-17 Josh Gottheimer D-New Jersey · house purchase $1,001 - $15,000
2023-04-17 Josh Gottheimer D-New Jersey · house Purchase $1,001 - $15,000
2022-06-15 Josh Gottheimer D-New Jersey · house purchase $1,001 - $15,000
2022-06-15 Josh Gottheimer D-New Jersey · house Purchase $1,001 - $15,000
9+ trades on file · most recent 2026-06-08

Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock

Stock awards & option exercises

2
stock awards · $208K market value
18
option exercises · $655K
2026-10-23 SCOTT ROBERT A Director AWARD 2,819 sh $88K
2026-07-15 Peetz Christopher Director AWARD 4,315 sh $120K
For ARQT, executives receive stock primarily as compensation rather than via open-market purchases — typical for established large-cap firms.

Bills Affecting ARQTLive legislation impacting this stock

Political ProfileWhere ARQT sits in Washington

[object Object]

STRUCTURAL: High regulatory density (95) from pharma sector and 8 identified revenue-impacting bills. No federal contracts, lobbying spend, or political donations. EVIDENTIARY: Significant doctor payments ($5.03M across 47,756 payments in 2024). Single congressional trader (C001123) with offsetting buy/sell transactions. Seven corporate insider buys in the last 180 days, all from non-C-suite personnel, totaling ~$313k. Net: High structural regulatory risk is offset by no direct political engagement and mixed, low-conviction trading signals.

Regulatory ExposureThreats & opportunities

Regulatory threats

  • Drug pricing and reimbursement legislation
    Congress, HHS/CMS
    "Recent bill_impacts list 8 pharma-sector bills with estimated revenue impacts up to $19.5M."

Regulatory opportunities

  • FDA approval and labeling for pipeline dermatology products
    FDA
    "Sector classification and lack of direct carveouts in `Recent bill_carveouts` suggests standard regulatory pathway is primary interface."

Capitol Hill AlliesChampions & critics

Congressional champions

Congressional critics

  • No specific congressional critics identified.
Member intelligence layer

Live signals + predictions for ARQT — for Founders

The free page above gives you the public record. Members see the real-time intelligence layer on top of it:

Become a Founder · $29.99/mo Locked rate forever · cancel anytime

Frequently AskedAbout ARQT & political exposure

Does Arcutis Biotherapeutics, Inc. (ARQT) hold federal contracts?
No direct prime contracts reported in USASpending.gov for Arcutis Biotherapeutics, Inc.. Companies in the semiconductor and AI hardware sectors often sell to the federal government via prime contractors and cloud resellers (Microsoft Azure, AWS, Lockheed Martin systems integration) rather than as direct primes.
Has Congress traded ARQT stock?
9 congressional trades by 2 unique members of Congress, most recently on 2026-05-29. See the Congressional Trading panel for politician-by-politician breakdown.
What is ARQT political risk profile?
Government dependence: 85/100. Lobbying intensity: 0/100. Political signal: neutral. Donor party split: R 0% / D 0%.
How does GovGreed track ARQT political activity?
GovGreed integrates STOCK Act congressional trade disclosures, FEC contributions, OGE executive-branch disclosures, USASpending federal contracts, Senate LDA lobbying filings, and SEC Form 4 corporate insider trades into a single queryable graph. ARQT data is updated daily from these official federal sources.